At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 99 enrolled
Drug / intervention
EDP-938 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART STUDY TO EVALUATE EDP-938 REGIMENS IN SUBJECTS AGED 28 DAYS TO 36 MONTHS INFECTED WITH RESPIRATORY SYNCYTIAL VIRUS (RSV)
In Brief
A Phase 2 clinical trial evaluating EDP-938 and Placebo for Respiratory Syncytial Virus (RSV). Completed, enrolled 99 participants across 78 sites in 15 countries.
Detailed Summary
A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in children with RSV infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Syncytial Virus (RSV)
CountriesArgentina, Australia, Brazil, Germany, Israel, Mexico, New Zealand, Poland, Romania, South Africa, South Korea, Spain, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedMar 2021
Enrollment StartApr 2022
Primary CompletionAug 2024
TodayJul 2026
First PostedMar 25, 2021
Enrollment StartApr 26, 2022
Primary CompletionAug 19, 2024
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 5.3 years ago
Interventions
EDP-938drug
Oral suspension
Placebodrug
Placebo oral suspension to match EDP-938